Moebiusol: From Architecture Services to In-House Innovation
2025 is a landmark year for Moebiusol, a company with nearly two decades of experience in medtech system architecture, regulatory-grade digital platforms, and telemedicine infrastructure. Originally established in 2006 to import premium German medical products, Moebiusol quickly evolved through key R&D projects—such as a portable telemedicine system developed with the Romanian Space Agency.
Today, Moebiusol is shifting focus from being purely a technology enabler for partners to a strategic player developing proprietary digital health products.
Acquisition of CCLMed: Foundation for Productization
At the start of 2025, Moebiusol acquired the assets and intellectual property of CCLMed, including a validated telemedicine system and a core patent. This acquisition provides a robust platform for Moebiusol's long-term vision: to deliver clinically meaningful digital tools built on proven infrastructure.
The CCLMed system will be enhanced and modularized, forming the technological foundation of new product developments in both B2B and B2C healthcare environments.
Launching In-House Products: The Personal Health Assistant
Moebiusol has officially started internal development of its first proprietary digital product — the Personal Health Assistant (PHA). Designed as an AI-augmented wellness companion, the PHA will help users monitor lifestyle metrics, track performance goals, and support chronic condition management.
Currently in the design and concept validation phase, the PHA combines machine learning models with privacy-aware architecture, making it accessible to both everyday users and health-conscious individuals seeking structured guidance.
Research Collaboration: Driving Real-World Impact
The company’s product vision is shaped by active participation in a clinical research collective led by Dr. Cosmin Sinescu in collaboration with the University of Medicine and Pharmacy Timișoara (UMF) and leading physicians and healthcare professionals.
This collaboration serves as the backbone for a new modular screening and monitoring platform, with the first module focusing on Oral HPV cancer screening and follow-up. Built as a hybrid platform for mobile screening, clinician interaction, and structured medical workflows, the solution is designed to scale into other HPV-related use cases over time.
Platform Highlights
- Cloud-native infrastructure with modular architecture
- Telemedicine-ready workflows with integrated device data
- Compliance with ISO 13485, GDPR, MDR, and FHIR-based interoperability
- AI-assisted decision support with full traceability
Looking Ahead
Moebiusol’s evolution from architecture consultancy to a developer of cutting-edge digital health solutions is driven by a commitment to innovation, regulatory compliance, and real-world usability. With in-house product development underway and strong academic-medical partnerships, the company is poised to shape the next generation of preventive healthcare technologies.